Scarica l'app Stockscreener
4.16
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BLUE Giù?
Forum
Previsione
Precedente Chiudi:
$4.16
Aprire:
$4.12
Volume 24 ore:
47,856
Relative Volume:
0.12
Capitalizzazione di mercato:
$38.18M
Reddito:
$21.73M
Utile/perdita netta:
$-91.17M
Rapporto P/E:
-5.6216
EPS:
-0.74
Flusso di cassa netto:
$-286.43M
1 W Prestazione:
+0.48%
1M Prestazione:
+8.05%
6M Prestazione:
-56.68%
1 anno Prestazione:
-77.21%
Intervallo 1D:
$4.0707
$4.20
Intervallo di 1 settimana:
$3.83
$4.565
Portata 52W:
$3.56
$28.60
Bluebird Bio Inc Stock (BLUE) Company Profile
Nome
Bluebird Bio Inc
Settore
Industria
Telefono
339-499-9300
Indirizzo
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Confronta BLUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
4.16 | 38.18M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-11-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Downgrade | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Iniziato | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-19 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Iniziato | JP Morgan | Overweight |
| 2023-03-07 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-07 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Reiterato | Barclays | Equal Weight |
| 2021-11-08 | Reiterato | Canaccord Genuity | Hold |
| 2021-11-08 | Downgrade | Goldman | Neutral → Sell |
| 2021-11-08 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Reiterato | Wedbush | Neutral |
| 2021-11-08 | Reiterato | Wells Fargo | Equal Weight |
| 2021-08-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Downgrade | Goldman | Buy → Neutral |
| 2021-08-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Ripresa | William Blair | Mkt Perform |
| 2021-08-09 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Downgrade | Berenberg | Buy → Hold |
| 2021-03-10 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-02-17 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-02-16 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-16 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Downgrade | Maxim Group | Buy → Hold |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Downgrade | Stifel | Buy → Hold |
| 2020-11-02 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Iniziato | Mizuho | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-27 | Aggiornamento | Stifel | Hold → Buy |
| 2020-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Ripresa | BofA/Merrill | Buy |
| 2020-02-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-10-01 | Iniziato | Stifel | Hold |
| 2019-08-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Aggiornamento | Maxim Group | Hold → Buy |
Mostra tutto
Bluebird Bio Inc Borsa (BLUE) Ultime notizie
Most US states OK Medicaid pilot for sickle cell gene therapies - The Boston Globe
Press Release Distribution & PR Platform - ACCESS Newswire
Gene Therapy For Rare Disease Market Set to Witness Significant - openPR.com
Drug and Gene Delivery Devices Market Future Business - openPR.com
Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organogenesis and moreResearchAndMarkets.com - CRISPR Medicine News
Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline - Yahoo Finance
bluebird bio opts to stay with Carlyle/SK takeover offer - The Pharma Letter
Bluebird says Ayrmid missed deadline for rival takeover bid - BioPharma Dive
bluebird bio's board opts for sale to U.S. investment firms - The Business Journals
Bluebird Bio Reaffirms Support for Carlyle Deal Amid Lack of Binding Offer From Ayrmid - marketscreener.com
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer - BioSpace
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird - Endpoints News
bluebird bio (BLUE) Board Endorses Deal Amid Ayrmid's Uncertaint - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - BioSpace
Bluebird Bio Says Ayrmid Failed To Submit Formal Offer, Confirms Carlyle, SK Deal; Stock Fell - Nasdaq
Bluebird bio shares fall amid acquisition woes - Investing.com Australia
Bluebird bio shares fall amid acquisition woes By Investing.com - Investing.com Canada
Tesla, Cal-Maine Foods, Bluebird Bio - TradingView
Bluebird Bio falls after Ayrmid fails to give binding offer - TradingView
bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9% - MSN
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquis - GuruFocus
Bluebird Bio (BLUE) Board Endorses Carlyle and SK Capital Acquisition Deal | BLUE Stock News - GuruFocus
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement | BLUE Stock News - GuruFocus
Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement - marketscreener.com
bluebird bio backs Carlyle and SK Capital takeover bid - Investing.com
Gene Therapy Market Insights 2025Trends, Growth Forecast & - openPR.com
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
Sickle Cell Disease Treatment Market to Hit $7.04 Billion By 2032 - openPR.com
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders - ACCESS Newswire
Biotechnology Company Grants Commercial License for Cell Manufacturing Platform Use to Advance SCD Therapy - Docwire News
Companies team up to support sickle cell gene therapy Lyfgenia - Sickle Cell Disease News
bluebird bio, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Gene Therapy Market Demand, Growth and Future Scope 2025-2032 | - openPR.com
Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking - Benzinga
Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar - MarketScreener
Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease - Business Wire
BlueBird Shares Are Up Today: What's Going On? - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps - Benzinga
Bluebird Bio Receives $4.50 Per Share Acquisition Proposal From Ayrmid - Nasdaq
bluebird bio’s SWOT analysis: biotech firm’s stock faces cash crunch, product potential - Investing.com
Bluebird bio rises on non-binding bid for up to $110.5 million - TradingView
Bluebird bio receives non-binding bid for up to $110.5 million - MSN
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates - MSN
Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize
Bluebird Bio Stock Leaps On Ayrmid Offer Amid Financial Strain - Finimize
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more - MSN
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more (T:NYSE) - Seeking Alpha
bluebird bio confirms rival takeover bid - The Pharma Letter
Bluebird Bio: A $110.5 Million Bid and the Future of Gene Therapy - AInvest
Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premiu - GuruFocus
Bluebird Bio Inc Azioni (BLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):